Cancer clinical trials in the region Normandie

103 currently recruiting clinical trials
Region Normandie

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3 Kidney cancer
#NCT06364631
Clear cell carcinoma Metastatic None 0 1 or 2 Systemic Treatment-Naive
7 main criterias to confirm
Centre François Baclesse (Caen )
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Breast cancer
#NCT05232916
HER2 Positive Localized Locally Advanced Other mutation None Targeted therapy Targeted therapy
Systemic Treatment-Naive Systemic Treatment-Naive
9 main criterias to confirm
Centre François Baclesse (Caen )
Greenwich LifeSciences, Inc.
Phase 3 Lung cancer
#NCT06430866
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Localized Locally Advanced Surgery Chemotherapy Surgery Chemotherapy
ALK EGFR ROS-1 Immunotherapy Immunotherapy
9 main criterias to confirm
Centre François Baclesse (Caen )
Amgen
Phase 3 Breast cancer
#NCT06393374
HER2 Negative HR Negative Localized Locally Advanced None Surgery Immunotherapy Chemotherapy Surgery Immunotherapy Chemotherapy
BRCA 1/2 Systemic Treatment-Naive Antibody Drug Conjugates (ADC) Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
10 main criterias to confirm
Centre François Baclesse (Caen ), Centre Henri Becquerel (Rouen )
Merck Sharp & Dohme LLC